EBS vs. JNJ, CLDX, DVAX, INVA, MNKD, NVAX, OPK, GERN, RGLS, and MYGN
Should you be buying Emergent Biosolutions stock or one of its competitors? The main competitors of Emergent Biosolutions include Johnson & Johnson (JNJ), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Innoviva (INVA), MannKind (MNKD), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), and Myriad Genetics (MYGN). These companies are all part of the "medical" sector.
Emergent Biosolutions vs. Its Competitors
Emergent Biosolutions (NYSE:EBS) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings.
Johnson & Johnson has higher revenue and earnings than Emergent Biosolutions. Emergent Biosolutions is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.
Johnson & Johnson has a net margin of 24.42% compared to Emergent Biosolutions' net margin of -13.63%. Johnson & Johnson's return on equity of 33.46% beat Emergent Biosolutions' return on equity.
78.4% of Emergent Biosolutions shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 1.2% of Emergent Biosolutions shares are owned by insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Johnson & Johnson had 108 more articles in the media than Emergent Biosolutions. MarketBeat recorded 114 mentions for Johnson & Johnson and 6 mentions for Emergent Biosolutions. Johnson & Johnson's average media sentiment score of 1.33 beat Emergent Biosolutions' score of 0.52 indicating that Johnson & Johnson is being referred to more favorably in the news media.
Emergent Biosolutions has a beta of 2.09, meaning that its share price is 109% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.
Emergent Biosolutions currently has a consensus price target of $14.33, indicating a potential upside of 94.85%. Johnson & Johnson has a consensus price target of $171.00, indicating a potential upside of 8.43%. Given Emergent Biosolutions' stronger consensus rating and higher possible upside, research analysts clearly believe Emergent Biosolutions is more favorable than Johnson & Johnson.
Summary
Johnson & Johnson beats Emergent Biosolutions on 12 of the 17 factors compared between the two stocks.
Get Emergent Biosolutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Emergent Biosolutions Competitors List
Related Companies and Tools
This page (NYSE:EBS) was last updated on 7/10/2025 by MarketBeat.com Staff
